Reuters -- GlaxoSmithKline Plc is to cut more costs and exit some areas of research in the face of tough generic competition, as a temporary boost from swine flu that buoyed fourth-quarter profits starts to dwindle.
Reuters -- GlaxoSmithKline Plc is to cut more costs and exit some areas of research in the face of tough generic competition, as a temporary boost from swine flu that buoyed fourth-quarter profits starts to dwindle.
